Clean Copy:

1. (original) A compound of Formula (**I**):



(I)

or pharmaceutically acceptable salt thereof, wherein:

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is H, aryl, arylalkyl-O-, arylalkyl-N(R^5)-, aryl-N(R^5)-, or heteroaryl, wherein said aryl is optionally substituted with up to two substituents selected from C_{1-8} alkyl, halogen, perhaloalkyl, and alkoxy;

R^4 is H, arylalkyl-O-, alkoxy, or aryloxy; and

R^5 is H, C_1-C_8 alkyl, aryl, C_{1-8} alkenyl, heteroaryl, arylalkyl, heteroarylalkyl, perhaloalkyl, or allyl;

with the provisos:

a) at least one of R^3 and R^4 is other than H;

b) when R^3 is arylalkyl-N(R^5)- or aryl-N(R^5)- and R^4 is H, then R^1 is H;

c) when R^1 is H, R^2 is CH_3 and R^3 is 2-chlorophenyl, then R^4 is other than H; and

d) when R^1 is H, R^2 is CH_3 and R^3 is 2-thienyl, then R^4 is other than methoxy.

2. (original) The compound of claim 1 wherein:

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is H, aryl, arylalkyl-O-, arylalkyl-N(R^5)-, or aryl-N(R^5)- wherein said aryl is optionally substituted with up to two substituents selected from C_{1-8} alkyl, halogen, perhaloalkyl, and alkoxy;

R^4 is H or aryloxy; and

R^5 is H, C_1-C_8 alkyl, aryl, C_{1-8} alkenyl, heteroaryl, arylalkyl, heteroarylalkyl, perhaloalkyl, or allyl.

3. (amended) A compound of claim 1 having Formula (**Ia**):



(Ia)

or pharmaceutically acceptable salt form thereof.

4. (amended) A compound of claim 1 having Formula (**Ib**):



(Ib)

or pharmaceutically acceptable salt form thereof.

5. (amended) The compound of claim 1 wherein:

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is arylalkyl-O-, arylalkyl-N(R^5)-, or aryl-N(R^5)-;

R^4 is H; and

R^5 is H, C_1-C_8 alkyl, aryl, C_{1-8} alkenyl, heteroaryl, arylalkyl, heteroarylalkyl, perhaloalkyl, or allyl.

6. (amended) The compound of claim 1 wherein:

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is arylalkyl-O-, arylalkyl-N(R^5)-, or aryl-N(R^5)-;

R^4 is H; and

R^5 is H, C_1-C_8 alkyl, or aryl.

7. (amended) The compound of claim 1 wherein:

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is arylalkyl-O-; and

R^4 is H.

8. (amended) The compound of claim 1 wherein:

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is H; and

R^4 is arylalkyl-O-.

9. (amended) The compound of claim 1 wherein:

R^1 is H;

R^2 is C_1-C_4 alkyl;

R^3 is arylalkyl-O-; and

R^4 is H.

10. (amended) The compound of claim 1 wherein:

R^1 is H;

R^2 is C_1-C_8 alkyl;

R^3 is arylalkyl-N(R^5)-;

R^4 is H; and

R^5 is H, C_1-C_8 alkyl, or aryl.

11. (amended) The compound of claim 1 wherein:

R^1 is H;

R^2 is methyl;

R^3 is phenyl, phenylalkyl-O-, phenylalkyl-N(R^5)-, or phenyl-N(R^5)-;

R^4 is H; and

R^5 is H.

12. (amended) The compound of claim 1 wherein:

R^1 is H;

R^2 is methyl;

R^3 is H; and

R^4 is phenylalkyl-O-.

13. (amended) The compound of claim 1 wherein:

R^1 is H;

R^2 is methyl;

R^3 is phenyl optionally substituted with up to two halogens, or R^3 is pyridinyl; and

R^4 is H or alkoxy.

14. (amended) The compound of claim 1 wherein:

R^1 is H;

R^2 is methyl;

R^3 is phenyl optionally substituted with up to two fluoro; and

R^4 is H or methoxy.

15. (amended) The compound of claim 1 wherein:

R^1 is H;

R^2 is methyl;

R^3 is pyridinyl; and

R^4 is H.

16. (original) A compound of any one of claims 1 to 4 selected from:

a) 7-benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

b) 1-methyl-7-(1-phenyl-ethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

c) 1-methyl-7-phenethyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

d) 1-methyl-7-(3-phenyl-propoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

e) benzyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

f) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(1'-phenyl-ethyl)-amine;

g) benzyl-methyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

h) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenethyl-amine;

i) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(3-phenyl-propyl)-amine;

j) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-amine; and

k) 1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

or pharmaceutically acceptable salt thereof.

17. (original) A compound of any one of claims 1 to 4 selected from:

m) 8-Benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

n) 7-Benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

o) 1-Methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

p) 7-Methoxy-1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

q) 8-(2-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

r) 8-(3-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

s) 8-(4-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

t) 8-(2,6-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

u) 8-(2,3-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

v) 8-(2,5-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

w) 1-Methyl-8-pyridin-3-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and

x) 1-Methyl-8-pyridin-2-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

or pharmaceutically acceptable salt thereof.

18. (amended) A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

19. (amended) A method of treating disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, sleep apnea or HDL-related condition comprising administering to a patient in need of said treating a therapeutically effective amount of a compound of claim 1.

20. (original) The method of claim 19 wherein the disorders of the central nervous system are selected from depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

21. (original) The method according to claim 19 wherein the disorder of the central nervous system is obesity.

22. (original) The method according to claim 19 wherein the sexual dysfunction is male erectile dysfunction.

23. (amended) A method of decreasing food intake of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.

24. (amended) A method of inducing satiety in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1..

25. (amended) A method of controlling weight gain of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1..

26. (amended) A method of treating obesity comprising administering to a patient in need of such treating a therapeutically effective amount of a compound of claim 1..

Claims 27 to 41 are cancelled.

42. (new) A method for preparing a pharmaceutical composition comprising the step of mixing a compounds of claim 1 and a pharmaceutically acceptable carrier.